{"id":684227,"date":"2022-09-12T12:43:33","date_gmt":"2022-09-12T16:43:33","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/protalix-biotherapeutics-to-present-in-person-at-the-h-c-wainwright-24th-annual-global-investment-conference\/"},"modified":"2022-09-12T12:43:33","modified_gmt":"2022-09-12T16:43:33","slug":"protalix-biotherapeutics-to-present-in-person-at-the-h-c-wainwright-24th-annual-global-investment-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/protalix-biotherapeutics-to-present-in-person-at-the-h-c-wainwright-24th-annual-global-investment-conference\/","title":{"rendered":"Protalix BioTherapeutics to Present in Person at the H.C. Wainwright 24th Annual Global Investment Conference"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>\n        <span class=\"legendSpanClass\">CARMIEL, <span class=\"xn-location\">Israel<\/span><\/span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">Sept. 12, 2022<\/span><\/span> \/PRNewswire\/ &#8212; Protalix BioTherapeutics, Inc. (NYSE\u00a0American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx<sup>\u00ae<\/sup> plant cell-based protein expression system, today announced that <span class=\"xn-person\">Dror Bashan<\/span>, the Company&#8217;s President and Chief Executive Officer, will present in person on Wednesday, September\u00a014, 2022 at 11:00\u00a0a.m. Eastern Daylight Time (EDT) at the H.C.\u00a0Wainwright 24th Annual Global Investment Conference, a hybrid conference. The conference is being held on September\u00a012-14, 2022 at the Lotte New York Palace Hotel in <span class=\"xn-location\">New York City<\/span>. Virtual participation will also be available.<\/p>\n<div id=\"prni_dvprnejpg74d3left\" dir=\"ltr\" style=\"width: 100%;text-align: left\">\n        <img decoding=\"async\" id=\"prnejpg74d3left\" style=\"width: 400px;height: 121px\" title=\"Protalix BioTherapeutics, Inc. Logo\" src=\"https:\/\/mma.prnewswire.com\/media\/999479\/Protalix_Biotherapeutics_Logo.jpg\" alt=\"Protalix BioTherapeutics, Inc. Logo\" align=\"middle\" \/>\n      <\/div>\n<p>\u00a0<\/p>\n<p>Mr.\u00a0Bashan will provide a live corporate overview at the conference, a webcast of which will be available on\u2013line. The live presentation replaces the pre-recorded presentation announced by the Company on September\u00a06, 2022.<\/p>\n<p>\n        <b>Live Presentation and Webcast Details:<\/b>\n      <\/p>\n<ul type=\"disc\">\n<li>Wednesday, September\u00a014, 2022 at 11:00\u00a0a.m. Eastern Daylight Time (EDT) in the Adams Room.<\/li>\n<li>Company Link: <a href=\"https:\/\/protalixbiotherapeutics.gcs-web.com\/events0\" target=\"_blank\" rel=\"nofollow noopener\">https:\/\/protalixbiotherapeutics.gcs-web.com\/events0<\/a><br \/>Webcast Link: <a href=\"https:\/\/journey.ct.events\/view\/326342b0-083d-4eca-81f7-f93cc78d3394\" target=\"_blank\" rel=\"nofollow noopener\">https:\/\/journey.ct.events\/view\/326342b0-083d-4eca-81f7-f93cc78d3394<\/a><\/li>\n<\/ul>\n<p>The live presentation webcast and the pre-recorded webcast will both be available for replay for at least two weeks on the Events Calendar of the Investors section of the Company&#8217;s website, at the above link.<\/p>\n<p>The Company&#8217;s management will participate in one-on-one meetings with investors who are registered to attend the conference. If you are an institutional investor and would like to attend the Company&#8217;s presentation, registration for the conference is available at <a href=\"https:\/\/hcwevents.com\/\" target=\"_blank\" rel=\"nofollow noopener\">https:\/\/hcwevents.com<\/a>. Once your registration is confirmed, you will be prompted to log onto the conference website to request a one-on-one meeting with the Company.<\/p>\n<p>\n        <b>About Protalix BioTherapeutics, Inc.<\/b>\n      <\/p>\n<p>Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. Protalix was the first company to gain U.S.\u00a0Food and Drug Administration (FDA) approval of a protein produced through plant cell-based in suspension expression system. Protalix&#8217;s unique expression system represents a new method for developing recombinant proteins in an industrial-scale manner.<\/p>\n<p>Protalix&#8217;s first product manufactured by ProCellEx, taliglucerase alfa, was approved by the FDA in <span class=\"xn-chron\">May 2012<\/span> and, subsequently, by the regulatory authorities of other countries. Protalix has licensed to Pfizer Inc. the worldwide development and commercialization rights for taliglucerase alfa, excluding <span class=\"xn-location\">Brazil<\/span>, where Protalix retains full rights.<\/p>\n<p>Protalix&#8217;s development pipeline consists of proprietary versions of recombinant therapeutic proteins that target established pharmaceutical markets, including the following product candidates: pegunigalsidase alfa, a modified stabilized version of the recombinant human \u03b1\u2013Galactosidase\u2013A protein for the treatment of Fabry disease; alidornase alfa or PRX\u2013110, for the treatment of various human respiratory diseases or conditions; PRX\u2013115, a plant cell-expressed recombinant PEGylated uricase for the treatment of severe gout; PRX\u2013119, a plant cell-expressed long action DNase\u00a0I for the treatment of NETs-related diseases; and others. Protalix has partnered with Chiesi Farmaceutici S.p.A., both in <span class=\"xn-location\">the United States<\/span> and outside <span class=\"xn-location\">the United States<\/span>, for the development and commercialization of pegunigalsidase alfa.<\/p>\n<p>\n        <b>Investor Contact<\/b><br \/>\n        <br \/>\n        <span class=\"xn-person\">Chuck Padala<\/span>, Managing Director<br \/>LifeSci Advisors<br \/>646-627-8390<br \/><a href=\"mailto:chuck@lifesciadvisors.com\" target=\"_blank\" rel=\"nofollow noopener\">chuck@lifesciadvisors.com<\/a><\/p>\n<p>Logo &#8211; <a href=\"https:\/\/mma.prnewswire.com\/media\/999479\/Protalix_Biotherapeutics_Logo.jpg\" target=\"_blank\" rel=\"nofollow noopener\">https:\/\/mma.prnewswire.com\/media\/999479\/Protalix_Biotherapeutics_Logo.jpg<\/a><\/p>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=LN69714&amp;sd=2022-09-12\" \/> View original content:<a id=\"PRNURL\" rel=\"nofollow noopener\" href=\"https:\/\/www.prnewswire.com\/news-releases\/protalix-biotherapeutics-to-present-in-person-at-the-hc-wainwright-24th-annual-global-investment-conference-301622194.html\" target=\"_blank\">https:\/\/www.prnewswire.com\/news-releases\/protalix-biotherapeutics-to-present-in-person-at-the-hc-wainwright-24th-annual-global-investment-conference-301622194.html<\/a><\/p>\n<p>SOURCE  Protalix BioTherapeutics, Inc.<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=LN69714&amp;Transmission_Id=202209121240PR_NEWS_USPR_____LN69714&amp;DateId=20220912\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire CARMIEL, Israel, Sept. 12, 2022 \/PRNewswire\/ &#8212; Protalix BioTherapeutics, Inc. (NYSE\u00a0American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx\u00ae plant cell-based protein expression system, today announced that Dror Bashan, the Company&#8217;s President and Chief Executive Officer, will present in person on Wednesday, September\u00a014, 2022 at 11:00\u00a0a.m. Eastern Daylight Time (EDT) at the H.C.\u00a0Wainwright 24th Annual Global Investment Conference, a hybrid conference. The conference is being held on September\u00a012-14, 2022 at the Lotte New York Palace Hotel in New York City. Virtual participation will also be available. \u00a0 Mr.\u00a0Bashan will provide a live corporate overview at the conference, a webcast of which will be available on\u2013line. The &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/protalix-biotherapeutics-to-present-in-person-at-the-h-c-wainwright-24th-annual-global-investment-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Protalix BioTherapeutics to Present in Person at the H.C. Wainwright 24th Annual Global Investment Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-684227","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.0 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Protalix BioTherapeutics to Present in Person at the H.C. Wainwright 24th Annual Global Investment Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/protalix-biotherapeutics-to-present-in-person-at-the-h-c-wainwright-24th-annual-global-investment-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Protalix BioTherapeutics to Present in Person at the H.C. Wainwright 24th Annual Global Investment Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire CARMIEL, Israel, Sept. 12, 2022 \/PRNewswire\/ &#8212; Protalix BioTherapeutics, Inc. (NYSE\u00a0American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx\u00ae plant cell-based protein expression system, today announced that Dror Bashan, the Company&#8217;s President and Chief Executive Officer, will present in person on Wednesday, September\u00a014, 2022 at 11:00\u00a0a.m. Eastern Daylight Time (EDT) at the H.C.\u00a0Wainwright 24th Annual Global Investment Conference, a hybrid conference. The conference is being held on September\u00a012-14, 2022 at the Lotte New York Palace Hotel in New York City. Virtual participation will also be available. \u00a0 Mr.\u00a0Bashan will provide a live corporate overview at the conference, a webcast of which will be available on\u2013line. The &hellip; Continue reading &quot;Protalix BioTherapeutics to Present in Person at the H.C. Wainwright 24th Annual Global Investment Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/protalix-biotherapeutics-to-present-in-person-at-the-h-c-wainwright-24th-annual-global-investment-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2022-09-12T16:43:33+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/999479\/Protalix_Biotherapeutics_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/protalix-biotherapeutics-to-present-in-person-at-the-h-c-wainwright-24th-annual-global-investment-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/protalix-biotherapeutics-to-present-in-person-at-the-h-c-wainwright-24th-annual-global-investment-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Protalix BioTherapeutics to Present in Person at the H.C. Wainwright 24th Annual Global Investment Conference\",\"datePublished\":\"2022-09-12T16:43:33+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/protalix-biotherapeutics-to-present-in-person-at-the-h-c-wainwright-24th-annual-global-investment-conference\\\/\"},\"wordCount\":555,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/protalix-biotherapeutics-to-present-in-person-at-the-h-c-wainwright-24th-annual-global-investment-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/999479\\\/Protalix_Biotherapeutics_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/protalix-biotherapeutics-to-present-in-person-at-the-h-c-wainwright-24th-annual-global-investment-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/protalix-biotherapeutics-to-present-in-person-at-the-h-c-wainwright-24th-annual-global-investment-conference\\\/\",\"name\":\"Protalix BioTherapeutics to Present in Person at the H.C. Wainwright 24th Annual Global Investment Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/protalix-biotherapeutics-to-present-in-person-at-the-h-c-wainwright-24th-annual-global-investment-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/protalix-biotherapeutics-to-present-in-person-at-the-h-c-wainwright-24th-annual-global-investment-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/999479\\\/Protalix_Biotherapeutics_Logo.jpg\",\"datePublished\":\"2022-09-12T16:43:33+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/protalix-biotherapeutics-to-present-in-person-at-the-h-c-wainwright-24th-annual-global-investment-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/protalix-biotherapeutics-to-present-in-person-at-the-h-c-wainwright-24th-annual-global-investment-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/protalix-biotherapeutics-to-present-in-person-at-the-h-c-wainwright-24th-annual-global-investment-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/999479\\\/Protalix_Biotherapeutics_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/999479\\\/Protalix_Biotherapeutics_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/protalix-biotherapeutics-to-present-in-person-at-the-h-c-wainwright-24th-annual-global-investment-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Protalix BioTherapeutics to Present in Person at the H.C. Wainwright 24th Annual Global Investment Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Protalix BioTherapeutics to Present in Person at the H.C. Wainwright 24th Annual Global Investment Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/protalix-biotherapeutics-to-present-in-person-at-the-h-c-wainwright-24th-annual-global-investment-conference\/","og_locale":"en_US","og_type":"article","og_title":"Protalix BioTherapeutics to Present in Person at the H.C. Wainwright 24th Annual Global Investment Conference - Market Newsdesk","og_description":"PR Newswire CARMIEL, Israel, Sept. 12, 2022 \/PRNewswire\/ &#8212; Protalix BioTherapeutics, Inc. (NYSE\u00a0American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx\u00ae plant cell-based protein expression system, today announced that Dror Bashan, the Company&#8217;s President and Chief Executive Officer, will present in person on Wednesday, September\u00a014, 2022 at 11:00\u00a0a.m. Eastern Daylight Time (EDT) at the H.C.\u00a0Wainwright 24th Annual Global Investment Conference, a hybrid conference. The conference is being held on September\u00a012-14, 2022 at the Lotte New York Palace Hotel in New York City. Virtual participation will also be available. \u00a0 Mr.\u00a0Bashan will provide a live corporate overview at the conference, a webcast of which will be available on\u2013line. The &hellip; Continue reading \"Protalix BioTherapeutics to Present in Person at the H.C. Wainwright 24th Annual Global Investment Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/protalix-biotherapeutics-to-present-in-person-at-the-h-c-wainwright-24th-annual-global-investment-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2022-09-12T16:43:33+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/999479\/Protalix_Biotherapeutics_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/protalix-biotherapeutics-to-present-in-person-at-the-h-c-wainwright-24th-annual-global-investment-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/protalix-biotherapeutics-to-present-in-person-at-the-h-c-wainwright-24th-annual-global-investment-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Protalix BioTherapeutics to Present in Person at the H.C. Wainwright 24th Annual Global Investment Conference","datePublished":"2022-09-12T16:43:33+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/protalix-biotherapeutics-to-present-in-person-at-the-h-c-wainwright-24th-annual-global-investment-conference\/"},"wordCount":555,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/protalix-biotherapeutics-to-present-in-person-at-the-h-c-wainwright-24th-annual-global-investment-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/999479\/Protalix_Biotherapeutics_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/protalix-biotherapeutics-to-present-in-person-at-the-h-c-wainwright-24th-annual-global-investment-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/protalix-biotherapeutics-to-present-in-person-at-the-h-c-wainwright-24th-annual-global-investment-conference\/","name":"Protalix BioTherapeutics to Present in Person at the H.C. Wainwright 24th Annual Global Investment Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/protalix-biotherapeutics-to-present-in-person-at-the-h-c-wainwright-24th-annual-global-investment-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/protalix-biotherapeutics-to-present-in-person-at-the-h-c-wainwright-24th-annual-global-investment-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/999479\/Protalix_Biotherapeutics_Logo.jpg","datePublished":"2022-09-12T16:43:33+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/protalix-biotherapeutics-to-present-in-person-at-the-h-c-wainwright-24th-annual-global-investment-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/protalix-biotherapeutics-to-present-in-person-at-the-h-c-wainwright-24th-annual-global-investment-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/protalix-biotherapeutics-to-present-in-person-at-the-h-c-wainwright-24th-annual-global-investment-conference\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/999479\/Protalix_Biotherapeutics_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/999479\/Protalix_Biotherapeutics_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/protalix-biotherapeutics-to-present-in-person-at-the-h-c-wainwright-24th-annual-global-investment-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Protalix BioTherapeutics to Present in Person at the H.C. Wainwright 24th Annual Global Investment Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/684227","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=684227"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/684227\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=684227"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=684227"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=684227"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}